Regeneron revised its earnings guidance for Eylea (aflibercept) for 2012, from $140 million to $160 million to a range of $250 million to $300 million, after the newly launched therapy for wet age-related macular degeneration had a strong performance in its first quarter of sales. The Tarrytown, N.Y.-based firm reported that 30,000 injections of Eylea had been given to date.